Related Experiment Video

Updated: Apr 30, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

7.2K

A perspective on molecular therapy in cholangiocarcinoma: present status and future directions

Jesper B Andersen1, Snorri S Thorgeirsson2

  • 1National Cancer Institute, Laboratory of Experimental Carcinogenesis, NIH, Building 37, Room 4146A, 37 Convent Drive, Bethesda, MD 20892-4262, USA ; Biotech Research & Innovation Centre, University of Copenhagen, DK-2200 Copenhagen, Denmark.

Hepatic Oncology
|April 29, 2014
PubMed

Insights

Cholangiocarcinoma (CCA) is a rare cancer lacking effective treatments. This review highlights current targeted therapy trials and promising genomic pathways for biliary tract cancers.

Area of Science:

  • Oncology
  • Genomics
  • Translational Medicine

Background:

  • Cholangiocarcinoma (CCA) is an orphan biliary tract cancer with poor prognosis and limited therapeutic options.
  • Current treatments are insufficient, with surgical resection being the only curative approach.
  • Existing clinical trials often use mixed cohorts, hindering targeted therapy development.

Purpose of the Study:

  • To review current clinical trials for targeted therapy in cholangiocarcinoma.
  • To identify promising new pathways for CCA treatment based on translational genomics.
  • To emphasize the need for marker-enriched trials for targeted therapy success.

Main Methods:

  • Review of current clinical trials for biliary tract cancers.
  • Analysis of translational genomics data to identify novel therapeutic targets.
  • Synthesis of information on treatment-refractory nature and genomic pathogenesis of CCA.

Main Results:

  • Limited understanding of CCA's genetic and genomic basis contributes to its treatment resistance.
  • Clinical trials are frequently underpowered due to mixed patient cohorts.
  • Translational genomics is revealing new candidate pathways for targeted intervention.

Conclusions:

  • There are currently no approved therapeutics for CCA, underscoring the urgent need for effective treatments.
  • Future clinical trials should be designed with specific biomarkers to enrich patient cohorts for targeted therapy.
  • Genomic insights offer promising avenues for developing novel, targeted therapies for cholangiocarcinoma.

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.9K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K